Report cover image

Advanced Gastric Carcinoma - Pipeline Insight, 2024

Publisher DelveInsight
Published Apr 01, 2024
Length 80 Pages
SKU # DEL18679188

Description

Advanced Gastric Carcinoma - Pipeline Insight, 2024



DelveInsight’s, “Advanced Gastric Carcinoma - Pipeline Insight, 2024,” report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Advanced Gastric Carcinoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered
  • Global coverage
Advanced Gastric Carcinoma Understanding

Advanced Gastric Carcinoma: Overview

Advanced stomach cancer means that a cancer that began in the stomach has spread to at least one other part of the body, such as the liver or lungs. Stomach cancer can spread to the: liver, lungs, lymph nodes, and tissue lining the abdominal cavity (peritoneum). The symptoms of advanced stomach cancer depend on what part of the body the cancer has spread to. The most common symptoms of stomach cancer include: unexplained weight loss, feeling and being sick, stomach pain, difficulty swallowing, feeling tired. Advanced stage means your stomach cancer has spread. External radiotherapy can help to control your cancer and reduce symptoms. Treatments such as chemotherapy or radiotherapy or targeted drugs can sometimes help to reduce symptoms. Other treatments such as laser therapy or stents can treat a blockage in the stomach. Surgery can help relieve symptoms of advanced stomach cancer if your cancer is causing a blockage. Laser therapy uses hot beams of light to burn away cancer cells. This can help control symptoms of advanced stomach cancer.

""Advanced Gastric Carcinoma - Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Advanced Gastric Carcinoma pipeline landscape is provided which includes the disease overview and Advanced Gastric Carcinoma treatment guidelines. The assessment part of the report embraces, in depth Advanced Gastric Carcinoma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Advanced Gastric Carcinoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights
  • The companies and academics are working to assess challenges and seek opportunities that could influence Advanced Gastric Carcinoma R&D. The therapies under development are focused on novel approaches to treat/improve Advanced Gastric Carcinoma.
Advanced Gastric Carcinoma Emerging Drugs Chapters

This segment of the Advanced Gastric Carcinoma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Advanced Gastric Carcinoma Emerging Drugs
  • Camrelizumab: Jiangsu Hengrui Medicine
Camrelizumab (formerly known as HR 301210, INCSHR 1210, SHR 1210) is a humanised high-affinity IgG4-kappa monoclonal antibody that targets the programmed cell death-1 receptor. Currently, it is in Phase III stage of clinical trial evaluation to treat advanced gastric or gastroesophageal junction adenocarcinoma.
  • Pamiparib: BeiGene
Pamiparib (BGB-290) is an investigational small molecule inhibitor of PARP1 and PARP2. Pamiparib is being evaluated as a monotherapy in pivotal clinical trials in China in recurrent platinum-sensitive and BRCA1/2 mutated ovarian cancers. It is currently in global clinical development as a monotherapy, and in combination with other agents, including BeiGene’s investigational anti-PD1 antibody, tislelizumab (BGB-A317), for a variety of solid tumor malignancies.

Further product details are provided in the report……..

Advanced Gastric Carcinoma: Therapeutic Assessment

This segment of the report provides insights about the different Advanced Gastric Carcinoma drugs segregated based on following parameters that define the scope of the report, such as:
  • Major Players in Advanced Gastric Carcinoma
There are approx. 50+ key companies which are developing the therapies for Advanced Gastric Carcinoma. The companies which have their Advanced Gastric Carcinoma drug candidates in the most advanced stage, i.e. phase III include, Jiangsu Hengrui Medicine.
  • Phases
DelveInsight’s report covers around 50+ products under different phases of clinical development like
  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration
Advanced Gastric Carcinoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
  • Oral
  • Parenteral
  • intravenous
  • Subcutaneous
  • Topical.
  • Molecule Type
Products have been categorized under various Molecule types such as
  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy
  • Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Advanced Gastric Carcinoma: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Advanced Gastric Carcinoma therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Advanced Gastric Carcinoma drugs.

Advanced Gastric Carcinoma Report Insights
  • Advanced Gastric Carcinoma Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs
Advanced Gastric Carcinoma Report Assessment
  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs
Key Questions

Current Treatment Scenario and Emerging Therapies:
  • How many companies are developing Advanced Gastric Carcinoma drugs?
  • How many Advanced Gastric Carcinoma drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Advanced Gastric Carcinoma?
  • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Advanced Gastric Carcinoma therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Advanced Gastric Carcinoma and their status?
  • What are the key designations that have been granted to the emerging drugs?
Key Players
  • Jiangsu Hengrui Medicine
  • BeiGene
  • CSPC ZhongQi Pharmaceutical Technology
  • LintonPharm Co.,Ltd.
  • Bristol-Myers Squibb
  • Hanmi Pharmaceutical
  • CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
  • Idience Co., Ltd.
  • Shanghai Henlius Biotech
  • AstraZeneca
  • Nanjing Legend Biotech Co.
  • ALX Oncology Inc.
  • Jiangsu Alphamab Biopharmaceuticals Co., Ltd
  • Genentech
  • Innovent Biologics (Suzhou) Co. Ltd.
  • Qilu Pharmaceutical Co., Ltd.
  • NextCure, Inc.
  • Chengdu Kanghong Biotech Co., Ltd.
  • GeneQuantum Healthcare (Suzhou) Co., Ltd.
  • Janssen Pharmaceutical K.K.
  • Shanghai Miracogen Inc.
  • Ambrx, Inc.
  • Imugene Limited
  • Vedanta Biosciences, Inc.
  • Celon Pharma SA
  • Bicycle Tx Limited
  • Seagen Inc.
Key Products
  • Camrelizumab
  • Pamiparib
  • Mitoxantrone Hydrochloride Liposome
  • Catumaxomab
  • Ipilimumab
  • Relatlimab
  • FLX475
  • DP303c
  • IDX-1197
  • HLX22
  • Olaparib
  • LCAR-C18S
  • ALX148
  • KN026
  • Atezolizumab
  • Sintilimab
  • QL1604
  • NC410
  • KH903
  • GQ1001
  • Amivantamab
  • IMU-131
  • BT8009
  • VE800
  • CPL304110
  • ARX788
  • MRG002
  • SEA-TGT

Table of Contents

80 Pages
Introduction
Executive Summary
Advanced Gastric Carcinoma: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Advanced Gastric Carcinoma – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Late Stage Products (Phase III)
Comparative Analysis
Camrelizumab: Jiangsu Hengrui Medicine
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
Pamiparib: BeiGene
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
Venadaparib: Idience
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Advanced Gastric Carcinoma Key Companies
Advanced Gastric Carcinoma Key Products
Advanced Gastric Carcinoma- Unmet Needs
Advanced Gastric Carcinoma- Market Drivers and Barriers
Advanced Gastric Carcinoma- Future Perspectives and Conclusion
Advanced Gastric Carcinoma Analyst Views
Advanced Gastric Carcinoma Key Companies
Appendix

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us